Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3578-3604

  Chen, X ^a   Hussain, S ^a   Parveen, S ^a   Zhang, S ^a   Yang, Y ^a   Zhu, C ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Activators; Diabetes; Diabetic complications; Glucose metabolism; Inhibitors; Insulin secretion resistance; Sulfonyl group

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 2 CYCLOHEXYL 1 (4 METHANESULFONYLPHENYL)CYCLOPROPANECARBOXYLIC ACID 2 THIAZOLYLAMIDE; ALDEHYDE REDUCTASE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; ENZYME ACTIVATOR; ENZYME INHIBITOR; GHRELIN RECEPTOR; GHRELIN RECEPTOR BLOCKING AGENT; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; INSULIN RECEPTOR KINASE; INSULIN RECEPTOR TYROSINE KINASE ACTIVATOR; KOTALANOL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) INHIBITOR; QUINAZOLINE DERIVATIVE; RO 281675; SALACINOL; SALCINOL; SULFONAMIDE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84863753093     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323225     Document Type: Review

References (238)

1. Humljan, J.; Kotnik, M.; Contreras-Martel, C; Blanot, D.; Urleb, U.; Dessen, A.a.; S olmajer, T.; Gobec, S. Novel naphthalene-N-sulfonyl-D-glutamic acid derivatives as inhibitors of MurD, a key peptidoglycan biosynthesis enzyme. J. Med. Chem., 2008, 51 (23), 7486-7494.
2. Jain, M.; Fan, J.; Baturay, N.Z.; Kwon, C.-H. Sulfonyl-Containing Aldophosphamide Analogues as Novel Anticancer Prodrugs Targeted against Cyclophosphamide-Resistant Tumor Cell Lines. J. Med. Chem., 2004, 47 (15), 3843-3852.
3. Wilkinson, B.L.; Innocenti, A.; Vullo, D.; Supuran, C.T; Poulsen, S.-A. Inhibition of Carbonic Anhydrases with Glycosyltriazole Benzene Sulfonamides. J. Med. Chem., 2008, 51 (6), 1945-1953.
4. Bachovchin, D.A.; Zuhl, A.M.; Speers, A.E.; Wolfe, M.R.; Weerapana, E.; Brown, S.J.; Rosen, H.; Cravatt, B.F. Discovery and Optimization of Sulfonyl Acrylonitriles as Selective, Covalent Inhibitors of Protein Phosphatase Methylesterase-1. J. Med. Chem., 2011, 54 (14), 5229-5236.
5. Alqasoumi, S.I.; Al-Taweel, A.M.; Alafeefy, A.M.; Ghorab, MM.; Noaman, E. Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents. Eur. J. Med. Chem., 2010, 45 (5), 1849-1853.
6. Supuran, C.T. Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides. Curr. Pharm. Des., 2008, 14 (7), 641-648.
7. Sikazwe, D.; Bondarev, M.L.; Dukat, M.; Rangisetty, J.B.; Roth, B.L.; Glennon, R.A. Binding of Sulfonyl-Containing Arylalkylamines at Human 5-HT6 Serotonin Receptors. J. Med. Chem., 2006, 49 (17), 5217-5225.
8. Glennon, R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem., 2003, 46 (14), 2795-2812.
9. Holloway, M.K.; Hunt, P.; McGaughey, G.B. Structure and modeling in the design of ß-and y-secretase inhibitors. Drug Dev. Res., 2009, 70 (2), 70-93.
10. Lee, J.; Song, L.; Terracina, G.; Bara, T.; Josien, H.; Asberom, T.; Sasikumar, T.K.; Burnett, D.A.; Clader, J.; Parker, EM.; Zhang, L. Identification of Presenilin 1-Selective y-Secretase Inhibitors with Reconstituted y-Secretase Complexes. Biochemistry, 2011, 50 (22), 4973-4980.
11. Silvestri, R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med. Res. Rev., 2009, 29 (2), 295-338.
12. MacMillan, K.S.; Naidoo, J.; Liang, J.; Melito, L.; Williams, N.S.; Morlock, L.; Huntington, P.J.; Estill, S.J.; Longgood, J.; Becker, G.L.; McKnight, S.L.; Pieper, A.A.; De Brabander, J.K.; Ready, JM. Development of Proneurogenic, Neuroprotective Small Molecules. J. Am. Chem. Soc., 2011, 133 (5), 1428-1437.
13. Jorissen, R.N.; Reddy, G.S.K.K.; Ali, A.; Altman, M.D.; Chellappan, S.; Anjum, S.G.; Tidor, B.; Schiffer, CA.; Rana, T.M.; Gilson, M.K. Additivity in the Analysis and Design of HIV Protease Inhibitors. J. Med. Chem., 2009, 52 (3), 737-754.
14. Piscitelli, F.; Coluccia, A.; Brancale, A.; La Regina, G.; Sansone, A.; Giordano, C; Balzarini, J.; Maga, G.; Zanoli, S.; Samuele, A.; Cirilli, R.; La Torre, F.; Lavecchia, A.; Novellino, E.; Silvestri, R. Indolylarylsulfones Bearing Natural and Unnatural Amino Acids. Discovery of Potent Inhibitors of HIV-1 Non-Nucleoside Wild Type and Resistant Mutant Strains Reverse Transcriptase and Coxsackie B4 Virus. J. Med. Chem., 2009, 52 (7), 1922-1934.
15. Hanefeld, M.; Fischer, S.; Julius, U.; Schulze, J.; Schwanebeck, U.; Schmechel, H.; Ziegelasch, H.J.; Lindner, J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 1996, 39 (12), 1577-1583.
16. Ortiz-Andrade, R.R.; Garcia-Jimenez, S.; Castillo-Espana, P.; Ramirez-Avila, G.; Villalobos-Molina, R.; Estrada-Soto, S. alpha-Glucosidase inhibitory activity of the methanolic extract from Tournefortia hartwegiana: an anti hyperglycemic agent. J. Ethnopharmacol, 2007, 109 (1), 48-53.
17. Jenkins, D.J.A.; Kendall, C.W.C; Augustin, L.S.A.; Franceschi, S.; Hamidi, M.; Marchie, A.; Jenkins, A.L.; Axelsen, M. Glycemic index: Overview of implications in health and disease. Am. J. Clin. Nutr, 2002, 76 (1), 266S-273S.
18. Pusztai, A.; Grant, G.; Duguid, T.; Brown, D.S.; Peumans, W.J.; van Damme, E.J.M.; Bardocz, S. Inhibition of starch digestion by {alpha}-amylase inhibitor reduces the efficiency of utilization of dietary proteins and lipids and retards the growth of rats. J. Nutr, 1995, 125 (6), 1554-1562.
19. Nichols, B.L.; Avery, S.E.; Karnsakul, W.; Jahoor, F.; Sen, P.; Swallow, DM.; Luginbuehl, U.; Hahn, D.; Sterchi, E.E. Congenital maltase-glucoamylase deficiency associated with lactase and sucrase deficiencies. J. Pediatr. Gastroenterol. Nutr, 2002, 35 (4), 573-579.
20. van de Laar, F.A. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag, 2008, 4 (6), 1189-1195.
21. Shihabudeen H., M.S.; Priscilla D., H.; Thirumurugan, K. Cinnamon extract inhibits.alpha.-glucosidase activity and dampens postprandial glucose excursion in diabetic rats. Nutr. Metab., 2011, 8 (1), doi: 10.1186/1743-7075-1188-1146
22. Yoshikawa, M.; Murakami, T.; Yashiro, K.; Matsuda, H. Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata. Chem. Pharm. Bull, 1998, 46 (8), 1339-1340.
23. Yuasa, H.; Takada, J.; Hashimoto, H. Glycosidase Inhibition by Cyclic Sulfonium Compounds. Bioorg. Med. Chem. Lett, 2001, 11 (9), 1137-1139.
24. Tanabe, G.; Yoshikai, K.; Hatanaka, T.; Yamamoto, M.; Shao, Y; Minematsu, T.; Muraoka, O.; Wang, T.; Matsuda, H.; Yoshikawa, M. Biological evaluation of de-O-sulfonated analogs of salacinol, the role of sulfate anion in the side chain on the a-glucosidase inhibitory activity. Bioorg. Med. Chem., 2007, 15 (11), 3926-3937.
25. Seo, W.D.; Kim, J.H.; Kang, J.E.; Ryu, H.W.; Curtis-Long, M.J.; Lee, H.S.; Yang, M.S.; Park, K.H. Sulfonamide chalcone as a new class of a-glucosidase inhibitors. Bioorg. Med. Chem. Lett, 2005, 15 (24), 5514-5516.
26. Wang, S.; Yan, J.; Wang, X.; Yang, Z.; Lin, F.; Zhang, T. Synthesis and evaluation of the [alpha]-glucosidase inhibitory activity of 3-[4-(phenylsulfonamido)benzoyl]-2H-1-benzopyran-2-one derivatives. Eur. J. Med. Chem., 2010, 45 (3), 1250-1255.
27. Luiken, J.J.F.P; Niessen, H.E.C.; Coort, S.L.M.; Hoebers, N; Coumans, W.A.; Schwenk, R.W.; Bonen, A.; Glatz, J.F.C. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem. J., 2009, 419 (2), 447-455.
28. McGarry, J.D.; Foster, D.W. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. Biochem., 1980, 49, 395-420.
29. McGarry, J.D.; Woeltje, K.F.; Kuwajima, M.; Foster, D.W. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab. Rev, 1989, 5 (3), 271-284.
30. Bremer, J. Carnitine-metabolism and functions. Physiol. Rev, 1983, 63 (4), 1420-1480.
31. McGarry, J.D.; Brown, N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem., 1997, 244 (1), 1-14.
32. Weis, B.C.; Cowan, A.T.; Brown, N; Foster, D.W.; McGarry, J.D. Use of a selective inhibitor of liver carnitine palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem., 1994, 269 (42), 26443-26448.
33. Hutchison, T.L.; Brouillette, W.J. Synthesis of 2-[6-(2, 4-Dinitrophenoxy)hexyl]oxiranecarboxylic acid: A selective carnitine palmitoyltransferase-1 inhibitor. Bioorg. Med. Chem., 1998, 6 (11), 2133-2138.
34. Giannessi, F.; Pessotto, P.; Tassoni, E.; Chiodi, P.; Conti, R.; De Angelis, F.; DellUomo, N; Catini, R.; Deias, R.; Tinti, M.O.; Carminati, P.; Arduini, A. Discovery of a Long-Chain Carbamoyl Amino carnitine Derivative, a Reversible Carnitine Palmitoyltransferase Inhibitor with Antiketotic and Antidiabetic Activity. J. Med. Chem., 2003, 46 (2), 303-309.
35. Giannessi, F.; Chiodi, P.; Marzi, M.; Minetti, P.; Pessotto, P.; De Angelis, F.; Tassoni, E.; Conti, R.; Giorgi, F.; Mabilia, M.; Dell'Uomo, N.; Muck, S.; Tinti, M.O.; Carminati, P.; Arduini, A. Reversible Carnitine Palmitoyltransferase Inhibitors with Broad Chemical Diversity as Potential Antidiabetic Agents. J. Med. Chem., 2001, 44 (15), 2383-2386.
36. Anderson, R.C.; Balestra, M.; Bell, P.A.; Deems, R.O.; Fillers, W.S.; Foley, J.E.; Fraser, J.D.; Mann, W.R.; Rudin, M.; Villhauer, E.B. Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. J. Med. Chem., 1995, 38 (18), 3448-3450.
37. DeFronzo, R.A.; Bonadonna, R.C.; Ferranini, E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care, 1992, 15 (3), 318-368.
38. Golay, A.; Swislocki, A.L.M.; Chen, Y.D.; Reaven, G.M. Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism., 1987, 36 (7), 692-696.
39. Foley, J.E. Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus. Diabetes Care, 1992, 15 (6), 773-784.
40. Anderson, R. Carnitine Palmitoyltransferase: A Viable Target for the Treatment of NIDDM? Curr. Pharm. Des., 1998, 4 (1), 1-16.
41. McGarry, J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diatetes, 2002, 51 (1), 7-18.
42. Esser, V.; Brown, N.; Cowan, A.T.; Foster, D.W.; McGarry, J.D. Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I). M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown adipocytes. J. Biol. Chem., 1996, 271 (12), 6972-6977.
43. Bressler, R.; Gay, R.; Copeland, J.G.; Bahl, J.J.; Bedotto, J.; Goldman, S. Chronic inhibition of fatty acid oxidation: New model of diastolic dysfunction. Life Sci., 1989, 44 (25), 1897-1906.
44. Bleicher, K.; Ceccarelli, S.M.; Chomienne, O.; Mattei, P.; Schulz-Gasch, T.; Stahl, C.M. Preparation of N-phenylsulfonamides as liver carnitine palmitoyl transferase 1 (L-CPT1) inhibitors for the treatment of hyperglycemia and glucose tolerance disorders. US20060276494, 2006.
45. Ackermann, J.; Bleicher, K.; Ceccarelli Grenz, S.M.; Chomienne, O.; Mattei, P.; Schulz-Gasch, T. Preparation of N-(benzenesulfonyl)-2, 3-dihydro-1H-indole-6-carboxamide derivatives as inhibitors of liver carnitine-dependent palmitoyltransferase 1 (L-CPT1). US20070060567, 2007.
46. Ackermann, J.; Bleicher, K.; Ceccarelli, S.M.; Chomienne, O.; Mattei, P.; Obst Sander, U. Preparation of phenylsulfonyl heterocycles as liver carnitine palmitoyl transferase 1 (L-CPT1) inhibitors. WO2007093507, 2007.
47. Ceccarelli, S.M.; Chomienne, O.; Mattei, P.; Obst Sander, U. Preparation of sulfonamide derivatives as inhibitors of liver carnitine palmitoyl transferase (L-CPT1). WO2008074692, 2008.
48. Matschinsky, F.M. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes, 1996, 45 (2), 223-241.
49. Matschinsky, F.M.; Glaser, B.; Magnuson, M.A. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes, 1998, 47 (3), 307-315.
50. Kamata, K.; Mitsuya, M.; Nishimura, T.; Eiki, J.I.; Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure, 2004, 12 (3), 429-438.
51. Guertin, K.R.; Grimsby, J. Small Molecule Glucokinase Activators as Glucose Lowering Agents: A New Paradigm for Diabetes Therapy. Curr. Med. Chem., 2006, 13 (15), 1839-1843.
52. Coghlan, M.; Leighton, B. Glucokinase activators in diabetes management. Exp. Opin. Invest. Drugs, 2008, 17 (2), 145-167.
53. Sarabu, R.; Berthel, S.J.; Kester, R.F.; Tilley, J.W. Glucokinase activators as new type 2 diabetes therapeutic agents. Exp. Opin. Ther. Patents, 2008, 18 (7), 759-768.
54. Efanov, A.M.; Barrett, D.G.; Brenner, B.M.; Briggs, S.L.; Delaunois, A.; Durbin, J.D.; Giese, U.; Guo, H.; Radloff, M.; Sanz, G.G.; Sewing, S.; Wang, Y.; Weichert, A.; Zaliani, A.; Gromada, J. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology, 2005, 136 (9), 2696-2701.
55. Bertram, L.S.; Black, D.; Briner, P.H.; Chatfield, R.; Cooke, A.; Fyfe, M.C.T.; Murray, P.J.; Naud, F.; Nawano, M.; Procter, M.J.; Rakipovski, G.; Rasamison, C.M.; Reynet, C.; Schofield, K.L.; Shah, V.K.; Spindler, F.; Taylor, A.; Turton, R.; Williams, G.M.; Wong-Kai-In, P.; Yasuda, K. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. J. Med. Chem., 2008, 51 (14), 4340-4345.
56. Grimsby, J.; Sarabu, R.; Corbett, W.L.; Haynes, N.E.; Bizzarro, F.T.; Coffey, J.W.; Guertin, K.R.; Hilliard, D.W.; Kester, R.F.; Mahaney, P.E.; Marcus, L.; Qi, L.D.; Spence, C.L.; Tengi, J.; Magnuson, M.A.; Chu, C.A.; Dvorozniak, M.T.; Matschinsky, F.M.; Grippo, J.F. Allosteric activators of glucokinase: potential role in diabetes therapy. Science, 2003, 301 (5631), 370-373.
57. Fyfe, M.C.T.; White, J.; Taylor, A.; Chatfield, R.; Wargent, E.; Printz, R.L.; Sulpice, T.; McCormack, J.G.; Procter, M.J.; Reynet, C.; Widdowson, P.S.; Wong-kai-in, P. Glucokinase activator PSNGK1 displays enhanced antihyperglycemic and insulinotropic actions. Diabetologia, 2007, 50 (6), 1277-1287.
58. Li, F.; Zhu, Q.; Zhang, Y.; Feng, Y.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4, 5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators. Bioorg. Med. Chem., 2010, 18 (11), 3875-3884.
59. Bebernitz, G.R.; Beaulieu, V.; Dale, B.A.; Deacon, R.; Duttaroy, A.; Gao, J.; Grondine, M.S.; Gupta, R.C.; Kakmak, M.; Kavana, M.; Kirman, L.C.; Liang, J.; Maniara, W.M.; Munshi, S.; Nadkarni, S.S.; Schuster, H.F.; Stams, T.; St. Denny, I.; Taslimi, P.M.; Vash, B.; Caplan, S.L. Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes. J. Med. Chem., 2009, 52 (19), 6142-6152.
60. Weichert, A.G.; Barrett, D.G.; Heuser, S.; Riedl, R.; Tebbe, M.J.; Zaliani, A. Substituted (Thiazol-2-yl)-Amide or Sulfonamide as Glycokinase Activators Useful in The Treatment Of Type 2 Diabetes. WO2004050645, 2004.
61. Weichert, A.G.; Barrett, D.G.; Heuser, S.; Riedl, R.; Tebbe, M.J.; Zaliani, A. Heteroaryl Compounds. WO2004063194, 2004.
62. Castelhano, A.L.; Dong, H.; Fyfe, M.C.T.; Gardner, L.S.; Kamikozawa, Y.; Kurabayashi, S.; Nawano, M.; Ohashi, R.; Procter, M.J.; Qiu, L.; Rasamison, C.M.; Schofield, K.L.; Shah, V.K.; Ueta, K.; Williams, G.M.; Witter, D.; Yasuda, K. Glucokinase-activating ureas. Bioorg. Med. Chem. Lett., 2005, 15 (5), 1501-1504.
63. Sidduri, A.; Grimsby, J.S.; Corbett, W.L.; Sarabu, R.; Grippo, J.F.; Lou, J.; Kester, R.F.; Dvorozniak, M.; Marcus, L.; Spence, C.; Racha, J.K.; Moore, D.J. 2, 3-Disubstituted acrylamides as potent glucokinase activators. Bioorg. Med. Chem. Lett., 2010, 20 (19), 5673-5676.
64. Iino, T.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorg. Med. Chem., 2009, 17 (7), 2733-2743.
65. Iino, T.; Hashimoto, N.; Sasaki, K.; Ohyama, S.; Yoshimoto, R.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. Structure-activity relationships of 3, 5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg. Med. Chem., 2009, 17 (11), 3800-3809.
66. Ishikawa, M.; Nonoshita, K.; Ogino, Y.; Nagae, Y.; Tsukahara, D.; Hosaka, H.; Maruki, H.; Ohyama, S.; Yoshimoto, R.; Sasaki, K.; Nagata, Y.; Eiki, J.i.; Nishimura, T. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19 (15), 4450-4454.
67. Takahashi, K.; Hashimoto, N.; Nakama, C.; Kamata, K.; Sasaki, K.; Yoshimoto, R.; Ohyama, S.; Hosaka, H.; Maruki, H.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. The design and optimization of a series of 2-(pyridin-2-yl)-1H- benzimidazole compounds as allosteric glucokinase activators. Bioorg. Med. Chem., 2009, 17 (19), 7042-7051.
68. Iino, T.; Sasaki, Y.; Bamba, M.; Mitsuya, M.; Ohno, A.; Kamata, K.; Hosaka, H.; Maruki, H.; Futamura, M.; Yoshimoto, R.; Ohyama, S.; Sasaki, K.; Chiba, M.; Ohtake, N.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19 (19), 5531-5538.
69. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402 (6762), 656-660.
70. Tschop, M.; Smiley, D.L.; Heiman, M.L. Ghrelin induces adiposity in rodents. Nature, 2000, 407 (6806), 908-913.
71. Nakazato, M.; Murakami, N.; Date, Y.; Kojima, M.; Matsuo, H.; Kangawa, K.; Matsukura, S. A role for ghrelin in the central regulation of feeding. Nature, 2001, 409 (6817), 194-198.
72. Fagot-Campagna, A.; Pettitt, D.J.; Engelgau, M.M.; Burrows, N.R.; Geiss, L.S.; Baldez, R.; Beckles, G.I.; Saaddine, J.; Gregg, E.W.; Williamson, D.F.; Narayan, K.M.V. Type 2 diabetes among North American children and adolescents: an epidemiological review and a public health perspective. J. Pediatr., 2000, 136 (5), 664-672.
73. Roth, C.L.; Reinehr, T. Roles of Gastrointestinal and Adipose Tissue Peptides in Childhood Obesity and Changes After Weight Loss Due to Lifestyle Intervention. Arch. Pediatr. Adolesc. Med., 2010, 164 (2), 131-138.
74. Golay, A.; Ybarra, J. Link between obesity and type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab., 2005, 19 (4), 649-663.
75. Rudolph, J.; Esler, W.P.; O'Connor, S.; Coish, P.D.G.; Wickens, P.L.; Brands, M.; Bierer, D.E.; Bloomquist, B.T.; Bondar, G.; Chen, L.; Chuang, C.-Y.; Claus, T.H.; Fathi, Z.; Fu, W.; Khire, U.R.; Kristie, J.A.; Liu, X.-G.; Lowe, D.B.; McClure, A.C.; Michels, M.; Ortiz, A.A.; Ramsden, P.D.; Schoenleber, R.W.; Shelekhin, T.E.; Vakalopoulos, A.; Tang, W.; Wang, L.; Yi, L.; Gardell, S.J.; Livingston, J.N.; Sweet, L.J.; Bullock, W.H. Quinazolinone Derivatives as Orally Available Ghrelin Receptor Antagonists for the Treatment of Diabetes and Obesity. J. Med. Chem., 2007, 50 (21), 5202-5216.
76. Esler, W.P.; Rudolph, J.; Claus, T.H.; Tang, W.; Barucci, N.; Brown, S.-E.; Bullock, W.; Daly, M.; DeCarr, L.; Li, Y.; Milardo, L.; Molstad, D.; Zhu, J.; Gardell, S.J.; Livingston, J.N.; Sweet, L.J. Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss. Endocrinology, 2007, 148 (11), 5175-5185.
77. Muller, A.F.; Janssen, J.A.; Hofland, L.J.; Lamberts, S.W.; Bidlingmaier, M.; Strasburger, C.J.; van der Lely, A.J. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J. Clin. Endocrinol. Metab., 2001, 86 (2), 590-593.
78. Svensson, J.; Lonn, L.; Jansson, J.O.; Murphy, G.; Wyss, D.; Krupa, D.; Cerchio, K.; Polvino, W.; Gertz, B.; Boseaus, I.; Sjostrom, L.; Bengtsson, B.A. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab., 1998, 83 (2), 362-369.
79. Serby, M.D.; Zhao, H.; Szczepankiewicz, B.G.; Kosogof, C.; Xin, Z.; Liu, B.; Liu, M.; Nelson, L.T.J.; Kaszubska, W.; Falls, H.D.; Schaefer, V.; Bush, E.N.; Shapiro, R.; Droz, B.A.; Knourek-Segel, V.E.; Fey, T.A.; Brune, M.E.; Beno, D.W.A.; Turner, T.M.; Collins, C.A.; Jacobson, P.B.; Sham, H.L.; Liu, G. 2, 4-Diaminopyrimidine Derivatives as Potent Growth Hormone Secretagogue Receptor Antagonists. J. Med. Chem., 2006, 49 (8), 2568-2578.
80. Liu, B.; Liu, M.; Xin, Z.; Zhao, H.; Serby, M.D.; Kosogof, C.; Nelson, L.T.J.; Szczepankiewicz, B.G.; Kaszubska, W.; Schaefer, V.G.; Falls, H.D.; Lin, C.W.; Collins, C.A.; Sham, H.L.; Liu, G. Optimization of 2, 4-diaminopyrimidines as GHS-R antagonists: Side chain exploration. Bioorg. Med. Chem. Lett., 2006, 16 (7), 1864-1868.
81. Pasternak, A.; Goble, S.D.; deJesus, R.K.; Hreniuk, D.L.; Chung, C.C.; Tota, M.R.; Mazur, P.; Feighner, S.D.; Howard, A.D.; Mills, S.G.; Yang, L. Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl) phenyl]benzenesulfonamide ghrelin receptor antagonists. Bioorg. Med. Chem. Lett., 2009, 19 (21), 6237-6240.
82. DeFronzo, R.A.; Ferrannini, E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14 (3), 173-194.
83. Consoli, A.; Nurjhan, N.; Capani, F.; Gerich, J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes, 1989, 38 (5), 550-557.
84. Cimbala, A.N.; Lamers, W.H.; Nelson, J.E.; Monahan, J.E.; Yoo-Warren, H.; Hanson, R.W. Rapid changes in the concentration of phosphoenolpyruvate carboxykinase mRNA in rat liver and kidney. Effects of insulin and cyclic AMP. J. Biol. Chem., 1982, 257 (13), 7629-7636.
85. Kita, K.; Nihei, C.; Tomitsuka, E. Parasite Mitochondria as Drug Target: Diversity and Dynamic Changes During the Life Cycle. Curr. Med. Chem., 2003, 10 (23), 2535-2548.
86. Owen, O.E.; Kalhan, S.C.; and Hanson, R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem., 2002, 277 (34), 30409-30412.
87. Curthoys, N.P.; Gstraunthaler, G. Mechanism of increased renal gene expression during metabolic acidosis. Am. J. Physiol. Renal Physiol., 2001, 281 (3), F381-F390.
88. Croset, M.; Rajas, F.; Zitoun, C.; Hurot, J.M.; Montano, S.; Mithieux, G. Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes, 2001, 50 (4), 740-746.
89. Gómez-Valadés, A.G.; Vidal-Alabró, A.; Molas, M.; Boada, J.; Bermúdez, J.; Bartrons, R.; Perales, J.C. Overcoming Diabetes-Induced Hyperglycemia through Inhibition of Hepatic Phosphoenolpyruvate Carboxykinase (GTP) with RNAi. Mol. Ther., 2006, 13 (2), 401-410.
90. Hanson, R.W.; Reshef, L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem., 1997, 66 (1), 581-611.
91. Foley, L.H.; Wang, P.; Dunten, P.; Ramsey, G.; Gubler, M.-L.; Wertheimer, S.J. Modified 3-Alkyl-1, 8-dibenzylxanthines as GTP-Competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett., 2003, 13 (20), 3607-3610.
92. Foley, L.H.; Wang, P.; Dunten, P.; Ramsey, G.; Gubler, M.-L.; Wertheimer, S.J. X-ray Structures of two xanthine inhibitors bound to PEPCK and N-3 modifications of substituted 1, 8-Dibenzylxanthines. Bioorg. Med. Chem. Lett., 2003, 13 (21), 3871-3874.
93. Pietranico, S.L.; Foley, L.H.; Huby, N.; Yun, W.; Dunten, P.; Vermeulen, J.; Wang, P.; Toth, K.; Ramsey, G.; Gubler, M.-L.; Wertheimer, S.J. C-8 Modifications of 3-alkyl-1, 8-dibenzylxanthines as inhibitors of human cytosolic phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett., 2007, 17 (14), 3835-3839.
94. Rosen, O.M. Banting lecture 1989. Structure and function of insulin receptors. Diabetes, 1989, 38 (12), 1508-1511.
95. Ward, C.; Lawrence, M.; Streltsov, V.; Garrett, T.; McKern, N.; Lou, M.Z.; Lovrecz, G.; Adams, T. Structural insights into ligand-induced activation of the insulin receptor. Acta Physiol. (Oxford) 2008, 192 (1), 3-9.
96. Moller, D.E.; Flier, J.S. Insulin resistance-mechanisms, syndromes, and implications. N. Engl. J. Med., 1991, 325 (13), 938-948.
97. Kahn, C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes, 1994, 43 (8), 1066-1084.
98. White, M.F. Regulating insulin signaling and beta-cell function through IRS proteins. Can. J. Physiol. Pharmacol., 2006, 84 (7), 725-737.
99. Di Guglielmo, G.M.; Drake, P.G.; Baass, P.C.; Authier, F.; Posner, B.I.; Bergeron, J.J. Insulin receptor internalization and signalling. Mol. Cell. Biochem., 1998, 182 (1-2), 59-63.
100. Manchem, V.P.; Goldfine, I.D.; Kohanski, R.A.; Cristobal, C.P.; Lum, R.T.; Schow, S.R.; Shi, S.; Spevak, W.R.; Laborde, E.; Toavs, D.K.; Villar, H.O.; Wick, M.M.; Kozlowski, M.R. A novel small molecule that directly sensitizes the insulin receptor in Vitro and in Vi Vo. Diabetes, 2001, 50 (4), 824-830.
101. Huang, S.; Czech, M.P. The GLUT4 glucose transporter. Cell Metab., 2007, 5 (4), 237-252.
102. Accili, D.; Drago, J.; Lee, E.J.; Johnson, M.D.; Cool, M.H.; Salvatore, P.; Asico, L.D.; Jose, P.A.; Taylor, S.; Westphal, H. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet, 1996, 12 (1), 106-109.
103. Laborde, E.; Manchem, V.P. Small Molecule Activators of the Insulin Receptor: Potential New Therapeutic Agents for the Treatment of Diabetes Mellitus. Curr. Med. Chem., 2002, 9 (24), 2231.
104. Pender, C; Goldfine, I.D.; Manchem, V.P.; Evans, J.L.; Spevak, W.R.; Shi, S.; Rao, S.; Bajjalieh, S.; Maddux, B.A.; Youngren, J.F. Regulation of Insulin Receptor Function by a Small Moleculen Insulin Receptor Activator. J. Biol. Chem., 2002, 277 (46), 43565-43571.
105. Lum, R.T.; Cheng, M.; Cristobal, C.P; Goldfine, I.D.; Evans, J.L.; Keck, J.G.; Macsata, R.W.; Manchem, V.P; Matsumoto, Y.; Park, S.J.; Rao, S.S.; Robinson, L.; Shi, S.; Spevak, W.R.; Schow, S.R. Design, Synthesis, and Structure-Activity Relationships of Novel Insulin Receptor Tyrosine Kinase Activators. J. Med. Chem., 2008, 51 (19), 6173-6187.
106. Dostert, A.; Heinzel, T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des., 2004, 10 (23), 2807-2816.
107. Kraus-Friedmann, N. Hormonal regulation of hepatic gluconeogenesis. Physiol. Rev., 1984, 64 (1), 170-259.
108. Smas, CM.; Chen, L.; Zhao, L.; Latasa, M.J.; Sul, H.S. Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation. J. Biol. Chem., 1999, 274 (18), 12632-12641.
109. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N.M.; Mullins, J. J.; Seckl, J.R.; Flier, J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science, 2001, 294 (5549), 2166-2170.
110. Sandeep, T.C.; Walker, B.R. Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends in Endocrinol. Metab., 2001, 12 (10), 446-453.
111. Albiston, A.L.; Obeyesekere, V.R.; Smith, R.E.; Krozowski, Z.S. Cloning and tissue distribution of the human 11 ß-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrin., 1994, 105 (1), 11-17.
112. Challis, J.R.; Connor, K. Glucocorticoids, 11beta-hydroxyster oid dehydrogenase: mother, fetus, or both? Endocrinology, 2009, 150 (3), 1073-1074.
113. Tomlinson, J.W.; Walker, E.A.; Bujalska, I.J.; Draper, N; Lavery, G.G.; Cooper, M. S.; Hewison, M.; Stewart, P.M. 11beta-hydroxyster oid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev., 2004, 25 (5), 831-866.
114. White, P. C.; Mune, T.; Agarwal, A.K. 11 beta-Hydro xyster o id dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev, 1997, 18 (1), 135-136.
115. Paterson, J.M.; Morton, N.M.; Fievet, C; Kenyon, C.J.; Holmes, M.C.; Staels, B.; Seckl, J.R.; Mullins, J.J. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 2004, 101 (18), 7088-7093.
116. Morton, N.M.; Paterson, J.M.; Masuzaki, H.; Holmes, M.C.; Staels, B.; Fievet, C; Walker, B.R.; Flier, J.S.; Mullins, J.J.; Seckl, J.R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes, 2004, 53 (4), 931-938.
117. Kotelevtsev, Y; Holmes, M.C.; Burchell, A.; Houston, P.M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C.R.W.; Seckl, J.R.; Mullins, J.J. 1 1beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A., 1997, 94 (26), 14924-14929.
118. St Jean, D.J.; Wang, M.; Fotsch, C. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome. Curr. Top. Med. Chem., 2008, 8 (17), 1508-1523.
119. Wamil, M.; Seckl, J.R. Inhibition of 11beta-hydroxy steroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today, 2007, 12 (13-14), 504-520.
120. Hale, C; Wang, M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini. Rev. Med. Chem., 2008, 8 (7), 702-710.
121. Ge, R.; Huang, Y; Liang, G.; Li, X. 11-beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development. Curr. Med. Chem., 2010, 17 (5), 412-422.
122. Barf, T; Vallgårda, J.; Emond, R.; Ha ggstro m, C; Kurz, G.; Nygren, A.; Larwood, V; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N; Ro nquist-Nii, Y; O hman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11 ß-Hydroxysteroid Dehydrogenase Type 1. J. Med. Chem., 2002, 45 (18), 3813-3815.
123. Alberts, P.; Engblom, L.; Edling, N; Forsgren, M.; Klingstrom, G.; Larsson, C; Ronquist-Nii, Y; Ohman, B.; Abrahmsen, L. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia, 2002, 45 (11), 1528-1532.
124. Alberts, P.; Nilsson, C; Selen, G.; Engblom, L.O.; Edling, N.H.; Norling, S.; Klingstrom, G.; Larsson, C; Forsgren, M.; Ashkzari, M.; Nilsson, CE.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L.B. Selective inhibition of 11 betahydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology, 2003, 144 (11), 4755-4762.
125. Xiang, J.; Ipek, M.; Suri, V; Massefski, W.; Pan, N; Ge, Y; Tam, M.; Xing, Y.; Tobin, J.F.; Xu, X. Synthesis and biological evaluation of sulfonamidooxazoles and ß-keto sulfones: selective inhibitors of 11 ß-hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett, 2005, 15 (11), 2865-2869.
126. Xiang, J.; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.; Huang, N; Zhang, Y; Tobin, J.; Mansour, T.S.; McKew, J. Keto sulfones as inhibitors of 11-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg. Med. Chem., 2007, 15 (13), 4396-4405.
127. Castro, A.; Zhu, J.X.; Alton, G.R.; Rejto, P.; Ermolieff, J. Assay optimization and kinetic profile of the human and the rabbit isoforms of 11beta-HSD1. Biochem. Biophys. Res. Commun., 2007, 357 (2), 561-566.
128. Siu, M.; Johnson, TO.; Wang, Y; Nair, S.K.; Taylor, W.D.; Cripps, S.J.; Matthews, J.J.; Edwards, M.P.; Pauly, T.A.; Ermolieff, J.; Castro, A.; Hosea, N. A.; LaPaglia, A.; Fanjul, A.N.; Vogel, J.E. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg. Med. Chem. Lett, 2009, 19 (13), 3493-3497.
129. Fotsch, C; Wang, M. Blockade of Glucocorticoid Excess at the Tissue Level: Inhibitors of 11 ß-Hydroxysteroid Dehydrogenase Type 1 as a Therapy for Type 2 Diabetes. J. Med. Chem., 2008, 51 (16), 4851-4857.
130. Sun, D.; Wang, Z.; Di, Y; Jaen, J.C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tomooka, CS.; Tu, H.; Ursu, S.; Walker, N; Yan, X.; Ye, Q.; Powers, J. P. Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11[beta]-Hydroxysteroid Dehydrogenase Type 1 (11[beta]-HSD1). Bioorg. Med. Chem. Lett, 2008, 18 (12), 3513-3516.
131. Tu, H.; Powers, J.P; Liu, J.; Ursu, S.; Sudom, A.; Yan, X.; Xu, H.; Meininger, D.; DeGraffenreid, M.; He, X. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11 ß-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem., 2008, 16 (19), 8922-8931.
132. Xiang, J.; Wan, Z.-K.; Li, H.-Q.; Ipek, M.; Binnun, E.; Nunez, J.; Chen, L.; McKew, J.C.; Mansour, T.S.; Xu, X.; Suri, V.; Tam, M.; Xing, Y; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine Sulfonamides as Potent, Selective, and Orally Available 11 ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitors with Efficacy in the Rat Cortisone-Induced Hyp er insulin emia Model. J. Med. Chem., 2008, 51 (14), 4068-4071.
133. Wan, Z.-K.; Chenail, E.; Xiang, J.; Li, H.-Q.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T.S.; Xu, X.; Tian, X.; Suri, V.; Hahm, S.; Xing, Y; Johnson, CE.; Li, X.; Qadri, A.; Panza, D.; Perreault, M.; Tobin, J.F; Saiah, E. Efficacious 11 ß-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model. J. Med. Chem., 2009, 52 (17), 5449-5461.
134. Yang, H. Y; Shen, Y; Chen, J.H.; Jiang, Q. F.; Leng, Y; Shen, J.H. Structure-based virtual screening for identification of novel 11ß-HSD1 inhibitors. Eur. J. Med. Chem., 2009, 44 (3), 1167-1171.
135. Zhang, X.; Zhou, Z.; Yang, H.; Chen, J.; Feng, Y; Du, L.; Leng, Y; Shen, J. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11[beta]-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. Bioorg. Med. Chem. Lett, 2009, 19 (15), 4455-4458.
136. Su, X.; Vicker, N; Ganeshapillai, D.; Smith, A.; Purohit, A.; Reed, M.J.; Potter, B.V. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol, 2006, 248 (1-2), 214-217.
137. Moreno-Díaz, H.; Villalobos-Molina, R.; Ortiz-Andrade, R.; Díaz-Coutiño, D.; Medina-Franco, J.L.; Webster, S.P; Binnie, M.; Estrada-Soto, S.; Ibarra-Barajas, M.; León-Rivera, I; Navarrete-Vázquez, G. Antidiabetic activity of N-(6-substituted-1, 3-benzothiazol-2-yl)benzenesulfonamides. Bioorg. Med. Chem. Lett, 2008, 18 (9), 2871-2877.
138. Neelamkavil, S.F; Boyle, CD.; Chackalamannil, S.; Greenlee, W.J.; Zhang, L.; Terracina, G. The discovery of azepane sulfonamides as potent 11ß-HSD1 inhibitors. Bioorg. Med. Chem. Lett, 2009, 19 (16), 4563-4565.
139. Saiah, E. The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors. Curr. Med. Chem., 2008, 15 (7), 642-649.
140. Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E.U.; Jacobson, P.; Link, J.T Adamantane sulfone and sulfonamide 11-[beta]-HSD1 Inhibitors. Bioorg. Med. Chem. Lett, 2007, 17 (2), 527-532.
141. Webster, S.P; Binnie, M.; McConnell, KMM.; Sooy, K.; Ward, P.; Greaney, M.F.; Vinter, A.; Pallin, T.D.; Dyke, H.J.; Gill, M.I.A.; Warner, I; Seckl, J.R.; Walker, B.R. Modulation of 11[beta]-hydroxysteroid dehydrogenase type 1 activity by 1, 5-substituted 1H-tetrazoles. Bioorg. Med. Chem. Lett, 2010, 20 (11), 3265-3271.
142. Vicker, N; Su, X.; Ganeshapillai, D.; Smith, A.; Purohit, A.; Reed, M.J.; Potter, B.V. Novel non-steroidal inhibitors of human 11betahydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol, 2007, 104 (3-5), 123-129.
143. Evans, J.L.; Jallal, B. Protein Tyrosine Phosphatases; Their Role in Insulin Action and Potential as Drug Targets. Exp. Opin. Invest. Drugs 1999, 8 (2), 139-160.
144. Neel, B.G.; Tonks, N.K. Protein tyrosine phosphatases in signal transduction. Curr. Opin. Cell Biol, 1997, 9 (2), 193-204.
145. Lee, S.; Wang, Q. Recent Development of Small Molecular Specic Inhibitor of ProteinTyrosine Phosphatase 1B. Med. Res. Rev., 2007, 27 (4), 553-573.
146. Ukkola, O.; Santaniemi, M. Protein Tyrosine Phosphatase 1B: A New Target for the Treatment of Obesity and Associated Co-Morbidities. J. Intern. Med, 2002, 252 (6), 467-475.
147. Goldstein, B.J. Protein-Tyrosine Phosphatases and the Regulation of Insulin Action. J. Cell. Biochem., 1992, 48 (1), 33-42.
148. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C.C; Ramachandran, C; Gresser, M.J.; Tremblay, M.L.; Kennedy, B.P Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein-Tyrosine Phosphatase-1B Gene. Science, 1999, 283 (5407), 1544-1548.
149. Klaman, L.D.; Boss, O.; Peroni, O.D.; Kim, J.K.; Martino, J.L.; Zabotny, J.M.; Moghal, N; Lubkin, M.; Kim, Y.B.; Sharpe, A.H.; Stricker-Krongrad, A.; Shulman, G.I.; Neel, B.G.; Kahn, B.B. Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice. Mol Cell. Biol, 2000, 20 (15), 5479-5489.
150. Cheng, A.; Dube, N; Gu, F.; Trembley, M.L. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem., 2002, 269 (4), 1050-1059.
151. Penninger, J.M.; Irie-Sasaki, J.; Sasaki, T.; Oliveira-dos-Santos, A. CD45: New jobs for an old acquaintance. J. Nat. Immunol, 2001, 2 (5), 389-396.
152. Tiganis, T.; Kemp, B.E.; Tonks, N.K. The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling. J. Biol. Chem., 1999, 274 (39), 27768-27775.
153. Taylor, S.D. Inhibitors of protein tyrosine phosphatase 1B (PTP1B). Curr. Top. Med. Chem., 2003, 3 (7), 759-782.
154. Hooft van Huijsduijnen, R.H.; Sauer, W.H.B.; Bombrun, A.; Swinnen, D. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs. J. Med. Chem., 2004, 47 (17), 4142-4146.
155. Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: Next-generation drugs? Angew. Chem. Int. Ed, 2005, 44 (25), 3814-3839.
156. Combs, A. P. Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of Diabetes, Obesity, and Cancer. J. Med. Chem., 2010, 53 (6), 2333-2344.
157. Liu, G. Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges. Curr. Med. Chem., 2003, 10 (15), 1407-1421.
158. Burke, T.R., Jr.; Kole, H.K.; Roller, P.P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun., 1994, 204 (1), 129-134.
159. Liu, D.-G.; Gao, Y; Voigt, J.H.; Lee, K.; Nicklaus, M.C.; Wu, L.; Zhang, Z.-Y; Burke, T.R. Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration. Bioorg. Med. Chem. Lett, 2003, 13 (18), 3005-3007.
160. Holmes, CP.; Li, X.; Pan, Y; Xu, C; Bhandari, A.; Moody, CM.; Miguel, J.A.; Ferla, S.W.; De Francisco, M.N.; Frederick, B.T.; Zhou, S.; Macher, N.; Jang, L.; Irvine, J.D.; Grove, J.R. Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors. Bioorg. Med. Chem. Lett, 2005, 15 (19), 4336-4341.
161. Romsicki, Y; Reece, M.; Gauthier, J.-Y; Asante-Appiah, E.; Kennedy, B.P. Protein tyrosine phosphatase-1B dephosphorylation of the insulin receptor occurs in a perinuclear endosome compartment in human embryonic kidney 293 cells. J. Biol. Chem., 2004, 279 (13), 12868-12875.
162. Hussain, M.; Ahmed, V; Hill, B.; Ahmed, Z.; Taylor, S.D. A re-examination of the difluoromethylenesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition. Bioorg. Med. Chem., 2008, 16 (14), 6764-6777.
163. Huang, P.; Ramphal, J.; Wei, J.; Liang, C; Jallal, B.; McMahon, G.; Tang, C. Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorg. Med. Chem., 2003, 11, 1835-1849.
164. Iversen, L.F.; Andersen, H.S.; Møller, K.B.; Olsen, O.H.; Peters, G.H.; Branner, S.; Mortensen, S.B.; Hansen, T.K.; Lau, J.; Ge, Y; Holsworth, D.D.; Newman, M.J.; Hundahl Møller, N.P Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochemistry, 2001, 40 (49), 14812-14820.
165. Liu, G.; Szczepankiewicz, B.G.; Pei, Z.; Janowick, D.A.; Xin, Z.; Hajduk, P.J.; Abad-Zapatero, C; Liang, H.; Hutchins, C.W.; Fesik, S.W.; Ballaron, S.J.; Stashko, M.A.; Lubben, T.; Mika, A.K.; Zinker, B.A.; Trevillyan, J.M.; Jirousek, M.R. Discovery and Structure-Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B. J. Med. Chem., 2003, 46 (11), 2093-2103.
166. Wilson, D.P; Wan, Z.-K.; Xu, W.-X.; Kirincich, S.J.; Follows, B.C.; Joseph-McCarthy, D.; Foreman, K.; Moretto, A.; Wu, J.; Zhu, M.; Binnun, E.; Zhang, Y.-L.; Tam, M.; Erbe, D.V; Tobin, J.; Xu, X.; Leung, L.; Shilling, A.; Tam, S.Y; Mansour, T.S.; Lee, J. Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second Phosphotyrosine Binding Site. J. Med. Chem., 2007, 50 (19), 4681-4698.
167. Coppola, GM.; Davies, J.W.; Jewell, CF., Jr.; Li, Y.-C; Wareing, J.R.; Sperbeck, D.M.; Stams, T.M.; Topiol, S.W.; Vlattas, I. Preparation of Substituted 1, 1-Dioxo-1, 2, 5-thiazolidine-3-ones as Protein Tyrosine Phosphatase 1b and T-Cell Protein Tyrosine Phosphatase Inhibitors to Mitigate Insulin Resistance in the Treatment of Diabetes or Atherosclerosis. WO2003082841, 2003.
168. Birch, A.M.; Kenny, P.W.; Morley, A.D.; Russell, D.J.; Toader, D. Preparation of 5-(Substituted phenyl)thiadiazolidin-3-ones as Inhibitors of Protein Tyrosine Phosphatase 1B. WO2004041799, 2004.
169. Saunders, J.O.; Miknis, G.F.; Blake, J.F. Preparation of Sulfahydantoins as Phosphate Isosteres for Use as Phosphatase Inhibitors in the Treatment of Cancer and Autoimmune Disorders. WO2004062664, 2004.
170. Combs, A.P.; Yue, E.W.T.; Bower, M.J.; Zhu, W.; Crawley, M.L.; Sparks, R.B.; Pruitt, J.R.; Takvorian, A. Inhibitors of Proteins That Bind Phosphorylated Molecules. WO2005035551, 2005.
171. Combs, A.P.; Yue, E.W.; Bower, M.; Ala, P.J.; Wayland, B.; Douty, B.; Takvorian, A.; Polam, P.; Wasserman, Z.; Zhu, W.; Crawley, M.L.; Pruitt, J.; Sparks, R.; Glass, B.; Modi, D.; McLaughlin, E.; Bostrom, L.; Li, M.; Galya, L.; Blom, K.; Hillman, M.; Gonneville, L.; Reid, B.G.; Wei, M.; Becker-Pasha, M.; Klabe, R.; Huber, R.; Li, Y.; Hollis, G.; Burn, T.C.; Wynn, R.; Liu, P.; Metcalf, B. Structure-Based Design and Discovery of Protein Tyrosine Phosphatase Inhibitors Incorporating Novel Isothiazolidinone Heterocyclic Phosphotyrosine Mimetics. J. Med. Chem., 2005, 48 (21), 6544-6548.
172. Yue, E.W.; Wayland, B.; Douty, B.; Crawley, M.L.; McLaughlin, E.; Takvorian, A.; Wasserman, Z.; Bower, M.J.; Wei, M.; Li, Y.; Ala, P.J.; Gonneville, L.; Wynn, R.; Burn, T.C.; Liu, P.C.C.; Combs, A.P. Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide scaffold. Bioorg. Med. Chem., 2006, 14 (17), 5833-5849.
173. Combs, A.P.; Zhu, W.; Crawley, M.L.; Glass, B.; Polam, P.; Sparks, R.B.; Modi, D.; Takvorian, A.; McLaughlin, E.; Yue, E.W.; Wasserman, Z.; Bower, M.; Wei, M.; Rupar, M.; Ala, P.J.; Reid, B.M.; Ellis, D.; Gonneville, L.; Emm, T.; Taylor, N.; Yeleswaram, S.; Li, Y.; Wynn, R.; Burn, T.C.; Hollis, G.; Liu, P.C.C.; Metcalf, B. Potent Benzimidazole Sulfonamide Protein Tyrosine Phosphatase 1B Inhibitors Containing the Heterocyclic (S)-Isothiazolidinone Phosphotyrosine Mimetic. J. Med. Chem., 2006, 49 (13), 3774-3789.
174. Sparks, R.B.; Polam, P.; Zhu, W.; Crawley, M.L.; Takvorian, A.; McLaughlin, E.; Wei, M.; Ala, P.J.; Gonneville, L.; Taylor, N.; Li, Y.; Wynn, R.; Burn, T.C.; Liu, P.C.C.; Combs, A.P. Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (3), 736-740.
175. Douty, B.; Wayland, B.; Ala, P.J.; Bower, M.J.; Pruitt, J.; Bostrom, L.; Wei, M.; Klabe, R.; Gonneville, L.; Wynn, R.; Burn, T.C.; Liu, P.C.C.; Combs, A.P.; Yue, E.W. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. Bioorg. Med. Chem. Lett., 2008, 18 (1), 66-71.
176. Navarrete-Vazquez, G.; Paoli, P.; León-Rivera, I.; Villalobos-Molina, R.; Medina-Franco, J.L.; Ortiz-Andrade, R.; Estrada-Soto, S.; Camici, G.; Diaz-Coutiño, D.; Gallardo-Ortiz, I.; Martinez-Mayorga, K.; Moreno-Díaz, H. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2- arylsulfonylaminobenzothiazoles with antihyperglycemic activity. Bioorg. Med. Chem., 2009, 17 (9), 3332-3341.
177. Wipf, P.; Aslan, D.C.; Southwick, E.C.; Lazo, J.S. Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases. Bioorg. Med. Chem. Lett., 2001, 11 (3), 313-317.
178. Barr, K.; Fahr, B.; Hansen, S.; Wiesmann, C. Compounds That Modulate the Activity of PTP-1B and TC-PTP. WO03073987, 2003.
179. Matteucci, E.; Giampietro, O. Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme. Curr. Med. Chem., 2009, 16 (23), 2943-2951.
180. Havale, S.H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem., 2009, 17 (5), 1783-1802.
181. Mentlein, R.; Gallwitz, B.; Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 1993, 214 (3), 829-835.
182. Weber, A.E. Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes. J. Med. Chem., 2004, 47 (17), 4135-4141.
183. Hansotia, T.; Baggio, L.; Yamada, Y.; Tsukiyama, K.; Preitner, F.; Thorens, B.; Seino, Y.; Drucker, D. Combined genetic disruption of dual incretin receptor signaling pathways reveals novel glucose lowering properties of DPP-IV inhibitors in mice. Diabetes, 2003, 52 (S1), A77-A78.
184. Fenyk-Melody, J.E.; Schmidt, K.; Bagchi, A.; Griffin, P.R.; Thornberry, N.A.; Sinha Roy, R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides. J. Biol. Chem., 2003, 278 (25), 22418-22423.
185. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.J.; Fischer, M.H.; Huaibing, H.; Hickey, G.J.; Kowalchick, J.E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, S.B.; Sinha Roy, R.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.; Zhu, L.; Thornberry, N.A.; Weber, A.E. (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48 (1), 141-151.
186. Feng, J.; Zhang, Z.; Wallace, M.B.; Stafford, J.A.; Kaldor, S.W.; Kassel, D.B.; Navre, M.; Shi, L.; Skene, R.J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D.R.; Gwaltney, S.L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase I V. J. Med. Chem., 2007, 50 (10), 2297-2300.
187. Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Burkey, B.F.; Dunning, B.E.; Prasad, K.; Mangold, B.L.; Russell, M.E.; Hughes, T.E. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem., 2003, 46 (13), 2774-2789.
188. Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G.E.; Egan, D.M.; Marc ink eviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48 (15), 5025-5037.
189. Parmee, E.R.; He, J.; Mastracchio, A.; Edmondson, S.D.; Colwell, L.; Eiermann, G.; Feeney, W.P; Habulihaz, B.; He, H.; Kilburn, R.; Leiting, B.; Lyons, K.; Marsilio, F.; Patel, R.A.; Petrov, A.; Di Salvo, J.; Wu, J.K.; Thornberry, N.A.; Weber, A.E. 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett, 2004, 14 (1), 43-46.
190. Ashton, W.T.; Dong, H.; Sisco, RM.; Doss, G.A.; Leiting, B.; Patel, R.A.; Wu, J.K.; Marsilio, F.; Thornberry, N.A.; Weber, A.E. Diastereoselective synthesis and configuration-dep end ent activity of (3-substituted-cycloalkyl) glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (4), 859-863.
191. Tsai, H.J.; Chou, S.-Y.; Chuang, S.-H.; Chen, C.-C; Hsu, F.-L. D-420720, A novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition. Drug Dev. Res., 2008, 69 (8), 514-519.
192. Zhao, G.; Taunk, P.C.; Magnin, D.R.; Simpkins, L.M.; Robl, J.A.; Wang, A.; Robertson, J.G.; Marc inkeviciene, J.; Sitkoff, D.F.; Parker, R.A.; Kirby, M.S.; Hamann, L.G. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2005, 15 (18), 3992-3995.
193. Pei, Z.; Li, X.; von Geldern, TW.; Longenecker, K.; Pireh, D.; Stewart, K.D.; Backes, B.J.; Lai, C; Lubben, T.H.; Ballaron, S.J.; Beno, D.W.A.; Kempf-Grote, A.J.; Sham, H.L.; Trevillyan, JM. Discovery and Structure-Activity Relationships of Piperidinone-and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors. J. Med. Chem., 2007, 50 (8), 1983-1987.
194. Backes, B.J.; Longenecker, K.; Hamilton, G.L.; Stewart, K.; Lai, C.; Kopecka, H.; von Geldern, T.W.; Madar, D.J.; Pei, Z.; Lubben, TH.; Zinker, B.A.; Tian, Z.; Ballaron, S.J.; Stashko, M.A.; Mika, A.K.; Beno, D.W.A.; Kempf-Grote, A.J.; Black-Schaefer, C.; Sham, H.L.; Trevillyan, JM. Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. Bioorg. Med. Chem. Lett, 2007, 17 (7), 2005-2012.
195. Nitta, A.; Fujii, H.; Sakami, S.; Nishimura, Y.; Ohyama, T; Satoh, M.; Nakaki, J.; Satoh, S.; Inada, C; Kozono, H.; Kumagai, H.; Shimamura, M.; Fukazawa, T.; Kawai, H. (3R)-3-Amino-4-(2, 4, 5-trifluorophenyl)-N-{4-[6-(2- methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett, 2008, 18 (20), 5435-5438.
196. Ahn, J.H.; Park, W.S.; Jun, M.A.; Shin, M.S.; Kang, S.K.; Kim, K. Y; Rhee, S.D.; Bae, M.A.; Kim, K.R.; Kim, S.G.; Kim, S.Y; Sohn, S.K.; Kang, N.S.; Lee, J.O.; Lee, D.H.; Cheon, H.G.; Kim, S.S. Synthesis and biological evaluation of homopiperazine derivatives with [beta]-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (24), 6525-6529.
197. Nordhoff, S.; Cerezo-Gálvez, S.; Deppe, H.; Hill, O.; López-Canet, M.; Rummey, C; Thiemann, M.; Matassa, V.G.; Edwards, PJ.; Feurer, A. Discovery of [beta]-homophenylalanine based pyrrolidin-2-ylm ethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. Lett, 2009, 19 (15), 4201-4203.
198. Shan, Z.; Peng, M.; Fan, H.; Lu, Q.; Lu, P.; Zhao, C; Chen, Y Discovery of potent dipeptidyl peptidase IV inhibitors derived from [beta]-aminoamides bearing substituted [1, 2, 3]-triazolopiperidines for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett, 2011, 21 (6), 1731-1735.
199. Edmondson, S.D.; Wei, L.; Xu, J.; Shang, J.; Xu, S.; Pang, J.; Chaudhary, A.; Dean, D.C.; He, H.; Leiting, B.; Lyons, K.A.; Patel, R.A.; Patel, S.B.; Scapin, G.; Wu, J.K.; Beconi, M.G.; Thornberry, N.A.; Weber, A.E. Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett, 2008, 18 (7), 2409-2413.
200. Edmondson, S.D.; Mastracchio, A.; Cox, J.M.; Eiermann, G.J.; He, H.; Lyons, K.A.; Patel, R.A.; Patel, S.B.; Petrov, A.; Scapin, G.; Wu, J.K.; Xu, S.; Zhu, B.; Thornberry, N.A.; Roy, R.S.; Weber, A.E. Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett, 2009, 19 (15), 4097-4101.
201. Miyamoto, Y; Banno, Y; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Funami, M.; Amano, M.; Yamamoto, Y; Aertgeerts, K.; Yano, J.; Maezaki, H. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorg. Med. Chem., 2011, 19 (1), 172-185.
202. Gabbay, K.H.; Merola, L.O.; Field, R.A. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science, 1966, 151 (3707), 209-210.
203. Nathan, DM. Long-term complications of diabetes mellitus. N. Engl. J. Med., 1988, 318 (20), 1315-1321.
204. van Heyningen, R. Formation of polyols by the lens of the lens of the rat with sugar cataract. Nature (Lond.), 1959, 184 (S4), 194-195.
205. King, H.; Aubert, R.E.; Herman, W.H. Global Burden of Diabetes, 1995-2025. Prevalence, Numeric Estimates, and Projections. Diabetes Care., 1998, 21 (9), 1414-1431.
206. Mahon, J.L.; Dupre, J.; Stiller, C.R. Lessons Learned from Use of Cyclosporine for Insulin-Dependent Diabetes Mellitus. Ann. N.Y. Acad. Sci., 1993, 696 (1), 351-363.
207. Brownlee, M. Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature, 2001, 414 (6865), 813-820.
208. Whiteside, C.I. Cellular Mechanisms and Treatment of Diabetes Vascular Complications Converge on Reactive Oxygen Species. Curr. Hypertens. Rep., 2005, 7 (2), 148-154.
209. Tomlinson, D.R.; Stevens, E.J.; Diemel, L.T. Aldose Reductase Inhibitors and Their Potential for the Treatment of Diabetic Complications. Trends Pharmacol. Sci., 1994, 15 (8), 293-297.
210. Kador, P.F. The Role of Aldose Reductase in the Development of Diabetic Complications. Med. Res. Rev., 1988, 8 (3), 325-352.
211. Kinoshita, J.H.; Nishimura, C. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Rev., 1988, 4 (4), 323-337.
212. Kador, P.F.; Kinoshita, J.H.; Sharpless, N.E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem., 1985, 28 (7), 841-849.
213. Alexiou, P.; Pegklidou, K.; Chatzopoulou, M.; Nicolaou, I.; Demopoulos, V.J. Aldose reductase enzyme and its implication tomajor health problems of the 21st century. Curr. Med. Chem., 2009, 16 (6), 734-752.
214. Hayman, S.; Kinoshita, J.H. Isolation and properties of lens aldose reductase. J. Biol. Chem., 1965, 240 (2), 877-882.
215. Dvornik, D.; Simard-Duquesne, N.; Keami, M.; Sestanj, K. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhaibitor. Science, 1973, 182 (4117), 1146-1148.
216. Sestanj, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Duquesne, N.; Dvornik, D. N-[5-(Trifluoromethyl)-6-methoxy-1- naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem., 1984, 27 (3), 255-256.
217. Kikkawa, R.; Hatanaka, I.; Yasuda, H.; Kobayashi, N.; Shigeta, Y.; Terashima, H.; Morimura, T.; Tsuboshima, M. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenyl-idene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia, 1983, 24 (4), 290-292.
218. Mylari, B.L.; Larson, E.R.; Beyer, T.A.; Zembrowski, W.J.; Aldinger, C.E.; Dee, M.F.; Siegel, T.W.; Singleton, D.H. Novel, potent aldose reductase inhibitors: 3, 4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J. Med. Chem., 1991, 34 (1), 108-122.
219. Ao, S.; Shingu, Y.; Kikuchi, C.; Takano, Y.; Nomura, K.; Fujiwara, T.; Ohkubo, Y.; Notsu, Y.; Yamaguchi, I. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism., 1991, 40 (1), 77-87.
220. Stribling, D.; Mirrlees, D.J.; Harrison, H.E.; Earl, D.C. Properties of ICI 128, 436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism., 1985, 34 (4), 336-344.
221. Van Zandt, M.C.; Jones, M.L.; Gunn, D.E.; Geraci, L.S.; Jones, J.H.; Sawicki, D.R.; Sredy, J.; Jacot, J.L.; DiCioccio, A.T.; Petrova, T.; Mitschler, A.; Podjarny, A.D. Discovery of 3-[(4, 5, 7-trifluorobenzothiazol-2-yl)methyl] indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J. Med. Chem., 2005, 48 (9), 3141-3152.
222. Da Settimo, F.; Primofiore, G.; La Motta, C.; Sartini, S.; Taliani, S.; Simorini, F.; Marini, A.M.; Lavecchia, A.; Novellino, E.; Boldrini, E. Naphtho[1, 2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors. J. Med. Chem., 2005, 48 (22), 6897-6907.
223. Pfister, J.R.; Wymann, W.E.; Mahoney, J.M.; Waterbury, L.D. Synthesis and Aldose Reductase Inhibitory Activity of 7-Sulfamoylxanthone-2-carboxylic Acids. J. Med. Chem., 1980, 23 (11), 1264-1267.
224. Mayfield, CA.; DeRuiter, J. Novel Inhibitors of Rat Lens Aldose Reductase: N-[[(Substituted amino) phenyl]sulfonyl]glycines. J. Med. Chem., 1987, 30 (9), 1595-1598.
225. Chen, X.; Zhu, C; Guo, F.; Qiu, X.; Yang, Y.; Zhang, S.; He, M.; Parveen, S.; Jing, C; Li, Y; Ma, B. Acetic Acid Derivatives of 3, 4-Dihydro-2H-1, 2, 4-benzothiadiazine 1, 1-Dioxide as a Novel Class of Potent Aldose Reductase Inhibitors. J. Med. Chem., 2010, 53 (23), 8330-8344.
226. Chen, X.; Yang, Y; Ma, B.; Zhang, S.; He, M.; Gui, D.; Hussain, S.; Jing, C; Zhu, C; Yu, Q.; Liu, Y Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold. Eur. J. Med. Chem., 2011, 46 (5), 1536-1544.
227. Chen, X.; Zhang, S.; Yang, Y; Hussain, S.; He, M.; Gui, D.; Ma, B.; Jing, C; Qiao, Z.; Zhu, C; Yu, Q. 1, 2-Benzothiazine 1, 1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase. Bioorg. Med. Chem., 2011, 19 (23), 7262-7269.
228. Miwa, I; Hirano, M.; Inagaki, K.; Belbeoch, C; Okuda, A.J. Development of potent aldose reductase Inhibitors having a hydantoin structure. Biochem. Pharmacol, 1987, 36 (17), 2789-2794.
229. Miwa, I; Hirano, M.; Kanbara, M.; Okuda, J. In vivo activities of aldose reductase inhibitors having a 1-(arylsulfonyl)hydantoin structure. Biochem. Pharmacol, 1990, 40 (2), 303-307.
230. Kato, K.; Nakayama, K.; Mizota, M.; Miwa, I; Okuda, J. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil. Chem. Pharm. Bull, 1991, 39 (6), 1540-1545.
231. Kato, K.; Nakayama, K.; Ohta, M.; Murakami, N; Murakami, K.; Mizota, M.; Miwa, I; Okuda, J. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur. J. Pharmacol, 1991, 193 (2), 185-191.
232. Brittain, D.R.; Brown, S.P; Cooper, A.L.; Longridge, J.L.; Morris, J.J.; Preston, J.; Slater, L. Phenylsulphone Derivatives. WO 9008761 (A1), 1991.
233. Cook, P.N.; Ward, W.H.J.; Petrash, J.M.; Mirrlees, D.J.; Sennitt, CM.; Carey, F.; Preston, J.; Brxttain, D.R.; Tuffin, D. P.; Howe, R. Kinetic characteristics of zeneca zd5522, a potent inhibitor of human and bovine lens aldose reductase. Biochem. Pharmacol, 1995, 49 (8), 1043-1049.
234. Inoue, J.; Cui, Y; Sakai, O.; Nakamura, Y; Kogiso, H.; Kador, P. Synthesis and aldose reductase inhibitory activities of novel Nnitromethylsulfonanilide derivatives. Bioorg. Med. Chem., 2000, 8 (8), 2167-2173.
235. Mylari, B.L.; Armento, S.J.; Beebe, D.A.; Conn, E.L.; Coutcher, J.B.; Dina, M.S.; O'Gorman, M.T.; Linhares, M.C.; Martin, W.H.; Oates, P.J.; Tess, D.A.; Withbroe, G.J.; Zembrowski, W.J. A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3- one. J. Med. Chem., 2003, 46 (12), 2283-2286.
236. Mylari, B.L.; Armento, S.J.; Beebe, D.A.; Conn, E.L.; Coutcher, J.B.; Dina, M.S.; O'Gorman, M.T.; Linhares, M.C.; Martin, W.H.; Oates, P.J.; Tess, D.A.; Withbroe, G.J.; Zembrowski, W.J. A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3- one and Congeners. J. Med. Chem., 2005, 48 (20), 6326-6339.
237. Alexiou, P.; Nicolaou, I; Stefek, M.; Kristl, A.; Demopoulos, V.J. Design and synthesis of N-(3, 5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg. Med. Chem., 2008, 16 (7), 3926-3932.
238. Bharatham, K.; Bharatham, N; Park, K.H.; Lee, K.W. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of a-glucosidase inhibitors. J. Mol Graph. Model, 2008, 26 (8), 1202-1212.